Dasatinib Tyrosine Kinase Inhibitor As Second and Third Line Therapy in Chronic Myeloid Leukemia: Outcome of a Nepalese Study. J Patan Acad Health Sci 2018, 5 (1), 47-56. https://doi.org/10.3126/jpahs.v5i1.24042.